Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Apr 2024 Status changed from active, no longer recruiting to completed.
08 Apr 2024 According to an Imbria Pharmaceuticals media release, results from this trial support initiation of the Phase 3 FORTITUDE-HCM clinical trial of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
08 Apr 2024 According to an Imbria Pharmaceuticals media release, results from the Phase 2 IMPROVE-HCM clinical trial were presented in a late-breaking clinical trial session at the American College of Cardiology Annual Scientific Session & Expo (ACC.24) and published in the Journal of the American College of Cardiology (JACC).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com